Fig. 3From: A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 yearsSubjects* with rSBA titers ≥1:8 at 7–10 years after the primary vaccination with MenACWY-TT or MenACWY-PS MenACWY meningococcal A, C, W, Y, PS polysaccharide, rSBA serum bactericidal antibody assay using baby rabbit complement, TT tetanus toxoid*In the according-to-protocol cohort for persistenceBack to article page